جست‌وجوی استاد و پژوهشگر

Norbert O. Reichمشاهده پروفایل

استاد

• Materials Chemistry
• Biochemistry & Biophysics
• Biomedical Sciences
• +۵ مورد دیگر

Norbert O. Reich is a Distinguished Professor in the Department of Chemistry & Biochemistry at the University of California, Santa Barbara (UCSB), affiliated with the College of Letters and Science. He joined UCSB in 1987 after completing his Ph.D. at UCSF in 1984 and an NIH postdoctoral fellowship there. His research focuses on enzyme mechanisms, particularly DNA methylation and telomerase, with applications in antibiotic and cancer therapy design. He also develops innovative chemical biology tools, including gold nanoshell-based drug delivery systems and fluorescence-based protein tracking methods. Education: Ph.D. in Chemistry from UCSF (1984). Awards: Regent's Junior Faculty Fellowship (1987), American Cancer Society Faculty Research Award (1991), UC President's Award for Excellence in Undergraduate Research (1994). Research Interests: Epigenetic regulation via DNA methylation in bacteria and mammals Enzyme mechanisms of DNA methyltransferases (e.g., DNMT3A, CcrM) Design of therapeutic inhibitors targeting epigenetic enzymes Light-controlled delivery of proteins/RNA via gold nanoshells Protein-DNA interaction analysis using microfluidic arrays Awards and Recognition: His honors reflect contributions to both research and education, emphasizing his dual impact in science and teaching. Lab and Collaborations: Leads the Reich Lab, collaborating with researchers like Tom Pettus (UCSB) and Erkki Ruoslahti. Projects include antibiotic development, cancer epigenetics, and nanotechnology-driven drug delivery. Future Work: Expanding applications of nanoshell technology for targeted gene silencing and exploring allosteric inhibitors of DNMT3A for cancer treatment.

• Cancer Drug Discovery
• Medicinal Chemistry
• Kinase Inhibitors
• +۴ مورد دیگر

Dr. Celine Cano is a research-focused academic at Newcastle University's Faculty of Medical Sciences within the School of Pharmacy and Biomedical Sciences, with a distinguished career spanning nearly two decades in cancer drug discovery and medicinal chemistry. Her work centers on developing targeted therapies, particularly kinase inhibitors and MDM2-p53 interaction antagonists, with significant contributions to understanding molecular mechanisms in oncology. Her research interests encompass cancer drug discovery , medicinal chemistry , and kinase inhibitor development , with specialized expertise in covalent drug design, fragment-based screening, and structural optimization of anticancer agents. Dr. Cano has pioneered work on MDM2-p53 inhibitors, ERK5 modulators, and PROTAC technologies, focusing on enhancing therapeutic indices while minimizing toxicity through precise molecular engineering. Analysis of her 15 most recent publications (2020-2024) reveals a dominant focus on targeted cancer therapies , particularly small-molecule antagonists of protein-protein interactions (MDM2-p53) and kinase inhibitors (ERK5, Nek2, NIK). Her work demonstrates consistent innovation in covalent drug design , pharmacokinetic optimization , and structural biology approaches to overcome resistance mechanisms. Notable trends include the development of differentiated pharmacokinetic profiles in next-generation MDM2 antagonists and sophisticated linker strategies for PROTACs. Dr. Cano maintains extensive collaborative networks across Newcastle University's cancer research ecosystem, particularly with groups led by Professors Ian Hardcastle, Bernard Golding, and Steve Wedge. Her research has been instrumental in advancing multiple drug candidates through preclinical development, with several publications describing compounds that have progressed to therapeutic evaluation.

Jonathan Weissmanمشاهده پروفایل

استاد

• Protein Folding
• Systems Biology
• Genomics
• +۶ مورد دیگر

Jonathan Weissman is a Professor of Biology at the Massachusetts Institute of Technology (MIT) and a Member of the Whitehead Institute. He is also an Investigator of the Howard Hughes Medical Institute and the Landon T. Clay Professor of Biology. His research spans protein folding mechanisms, ribosome profiling, CRISPR-based tools (CRISPRi/a), and genetic interaction mapping. Whitehead Institute Member MIT Professor HHMI Investigator Co-founder, Maze Therapeutics & KSQ Therapeutics Research Interests focus on: Protein folding in cellular contexts Endoplasmic reticulum (ER) function and stress responses Genome-wide CRISPR screening for gene regulation High-density genetic interaction maps in mammals Mitochondrial protein targeting and quality control Epigenomic engineering with synthetic tools Scientific Awards include: Protein Society Irving Sigal Young Investigator Award (2004) Raymond & Beverly Sackler Prize (2008) National Academy of Sciences election (2009) NAS Award for Scientific Discovery (2015) Genetics Society of America Ira Herskowitz Award (2020) Labs & Collaborations : Leads the Weissman Lab at MIT/Whitehead Institute, co-leads the Laboratory for Genomic Research with GlaxoSmithKline, and chairs the Stowers Institute Scientific Advisory Board.

Samuel Fountainمشاهده پروفایل

استاد

• Pharmacology
• Ion Channels
• Cardiometabolic Physiology
• +۱۲ مورد دیگر

Professor Samuel Fountain is a leading academic in pharmacology at the University of East Anglia, where he serves as Chair of Pharmacology within the School of Biological Sciences. He holds additional leadership roles as Associate Pro-Vice-Chancellor of the UEA Doctoral College and has previously served as Associate Dean for Postgraduate Research and Director of the Biomedical Research Centre. He is actively supervising multiple PhD students and securing major research funding. BSc (Hons) Pharmacology, University of Leeds (1997–2000) MRC-funded PhD, University of Leeds (2000–2004) Wellcome Trust Research Associate, University of Manchester (2004–2008) BBSRC David Phillips Fellow, University of Leeds (2008–2010) Lecturer to Professor of Pharmacology, University of East Anglia (2010–present) His research focuses on the role of ion channels—particularly P2X receptors—in vascular and adipose tissues, with implications for cardiometabolic diseases. His work integrates pharmacology, physiology, and molecular biology to understand neurovascular and neuroadipose communication, receptor-ligand interactions, and drug discovery. He employs techniques such as pressure myography, patch-clamp electrophysiology, calcium imaging, and molecular modelling. The analysis of his recent publications reveals a strong emphasis on purinergic signalling, ion channel pharmacology, and autonomic control of blood vessels and fat tissue. His work bridges basic science with translational applications, particularly in hypertension, obesity, and metabolic syndrome. Collaborations with AstraZeneca, Merck, and the British Heart Foundation underscore the clinical and pharmaceutical relevance of his research. Notable scientific recognition includes the prestigious BBSRC David Phillips Fellowship. He also contributes to the academic community through editorial roles, including as Editor of Purinergic Signalling , and as a member of the British Pharmacological Society and The Physiological Society. Professor Fountain actively mentors postdoctoral researchers and PhD students, several of whom are funded by BBSRC, BHF, and AstraZeneca iCASE awards. His lab is supported by significant grants from the British Heart Foundation, BBSRC, and industry partners, enabling cutting-edge research in vascular and metabolic pharmacology. He leads multiple active projects on neurovascular transmission, purinergic control, and drug discovery for P2X receptors. His research group operates within the Cells and Tissues research theme at UEA and utilizes advanced experimental platforms including human tissue studies, high-throughput screening, and computational ligand docking. The lab fosters interdisciplinary collaboration between pharmacologists, physiologists, and clinicians, positioning it at the forefront of autonomic and metabolic research.

Adrian Whittyمشاهده پروفایل

دانشیار

• Biochemistry
• Structural Biology
• Drug Discovery
• +۳ مورد دیگر

Adrian Whitty is an Associate Professor in the Department of Biology at Boston University . His research focuses on protein-protein and protein-ligand recognition, particularly in developing mechanistic understandings of growth factor receptor activation and advancing drug discovery for protein-protein interaction inhibition. Education: B.Sc. (Honors) in Chemistry from King’s College, University of London (1985); Ph.D. in Organic Chemistry from the University of Illinois at Chicago (1991); Postdoctoral Research Fellow at Brandeis University's Biochemistry Department (1990-93). His work integrates biochemical and cell-based assays using advanced technologies like FRET, Time-Resolved Fluorescence, and Surface Plasmon Resonance (Biacore 3000). He collaborates with computational chemists, organic synthesis experts, X-ray crystallographers, and biologists to develop novel approaches for designing small molecule inhibitors of protein-protein interactions. Recent publications highlight trends in machine learning applications for molecular scientists, structural analysis of enzyme mechanisms, macrocycle-based drug design, and quantitative studies of protein interaction energetics. His lab emphasizes rigorous hypothesis-driven experimental design, preparing students for careers in academia or industry. Advisory and leadership roles include membership in The Protein Society (2008-present), the American Society of Biochemistry and Molecular Biology (ASBMB) Governing Council (2007-present), and founding roles in the Council for Systems Biology in Boston (CSB2) and the Institute for Chemical Biology and Drug Discovery at SUNY Stony Brook. His laboratory is equipped with state-of-the-art facilities for fluorescence, analytical ultracentrifugation (AUC), dynamic light scattering (DLS), isothermal titration calorimetry (ITC), and tissue culture, supporting diverse techniques including flow cytometry and reaction pathway modeling with Mathematica and MATLAB.

David M. Smithمشاهده پروفایل

استاد

• Proteasome Function
• Cancer Biology
• Neurodegenerative Diseases
• +۳ مورد دیگر

David M. Smith is a Professor at the West Virginia University School of Medicine , holding dual appointments in the Biochemistry and Molecular Medicine and Neuroscience departments. He is also a member of the WVU Cancer Institute and affiliated with the Rockefeller Neuroscience Institute . PhD from the University of South Florida School of Medicine Postdoctoral training at Harvard Medical School Research Focus : Molecular mechanisms of proteasome function, including substrate recognition, unfolding, and degradation. His work bridges fundamental enzymology with translational applications in cancer therapy and neurodegenerative diseases like Alzheimer's and Parkinson's. Key Article Trends : Recent publications emphasize proteasome activation mechanisms , neurodegenerative disease models , and structural insights into ATPase function . Grants : NIH R01 GM107129 (Mechanisms regulating proteasomal degradation), NIH R01 AG064188 (Proteasome function in Alzheimer's), and collaborations on projects like Protein-unfolding chaperones for blindness treatment . Lab Personnel : Includes graduate students Thomas Bradley, David Salcedo-Tacuma, Giovanni Howells, and Md Qamrul Islam, along with research technicians and undergraduates. Training emphasizes biochemical, biophysical, and computational techniques.

• Cancer Metabolism
• Metabolic Reprogramming
• Tumor Metastasis
• +۳ مورد دیگر

Sophia Lunt is a Professor in the Department of Biochemistry & Molecular Biology and Chemical Engineering & Materials Science at Michigan State University , where she has been since 2015 (Assistant Professor 2015-2021, Associate Professor 2021-2025, Professor 2025-present). She leads the Lunt Lab , focusing on cancer metabolism , particularly metabolic reprogramming in tumor proliferation, heterogeneity, and metastasis . Her work combines mass spectrometry , genetic cancer models , cell biology , and fluorescent agents to develop targeted cancer therapies . Ph.D. (2010) & B.S. (2005) in Chemistry Postdoctoral Fellow at MIT (2010-2015) NSF CAREER awardee (2019) 20+ peer-reviewed publications since 2007 Research Focus : Cancer metabolism (Warburg effect, PHGDH heterogeneity, TIGAR regulation) Photodynamic therapy (counterion-tuned agents, metal halide nanoclusters) Metabolomics (tumor-immune interactions, microbiome effects) Selected Scientific Awards : 2022 MSU College of Natural Science Teacher-Scholar Award 2022 MSU BMB Teaching Award 2020 MANA Young Investigator Award 2019 NSF CAREER & METAvivor Early Career Investigator Awards Her teaching includes BMB 101: Frontiers in Biochemistry (curriculum overhaul for freshman success) and BMB 461: Advanced Biochemistry I , covering metabolic regulation and pathways.

• Structural Biology
• Biochemistry
• Molecular Biology
• +۳ مورد دیگر

Nancy C. Horton is a Professor in the Department of Molecular and Cellular Biology at the University of Arizona, with joint faculty appointments in Biochemistry. Her research focuses on understanding the structures and mechanisms of proteins involved in DNA and RNA processing, particularly enzymes that modulate their activity through filament formation. She leads the Horton Lab, which employs structural techniques like X-ray crystallography, NMR, and cryo-electron microscopy alongside biochemical and high-throughput methods. Dr. Horton received her B.S. in Chemistry from Southern Illinois University (1986) and Ph.D. in Biological Chemistry from the University of Pennsylvania (1994). She completed postdoctoral training at The Upjohn Company and the University of California, Santa Barbara, before establishing her independent lab at the University of Arizona in 2001. Her work has contributed significantly to understanding enzyme filamentation in cellular defense mechanisms and host-virus interactions, particularly with Human Parvovirus B19. Research interests include structural biology, biophysics, and the functional implications of protein filaments. Her lab has elucidated the structural basis of enzyme activation via filamentation and its role in DNA cleavage specificity. She also engages in education initiatives, teaching courses on the molecular basis of life and professional development for graduate students. Key contributions include the discovery of enzyme filamentation as a regulatory mechanism and structural studies of SgrAI and NS1 proteins. The lab collaborates broadly, leveraging multi-scale modeling and experimental approaches to study macromolecular complexes. Dr. Horton’s work bridges basic science and translational research, with implications for antiviral drug development and understanding fundamental biological processes.

Graham Laddsمشاهده پروفایل

استاد

• Pharmacology
• G protein-coupled receptors
• Signal Bias
• +۵ مورد دیگر

Professor Graham Ladds is a Professor of Receptor Pharmacology at the University of Cambridge's Department of Pharmacology and Fellow of St John's College. He serves as Co-Director of the Cambridge Academy of Therapeutic Science and Director of Studies for Pharmacology. His academic journey includes a BSc in Biochemistry from the University of Birmingham and PhD in yeast pheromone signalling from the University of Warwick, where he progressed to Associate Professor before joining Cambridge in 2015. His research focuses on G protein-coupled receptor (GPCR) pharmacology, specializing in: Agonist bias mechanisms and signaling dynamics Mathematical modeling of receptor-ligand interactions RAMPs (Receptor Activity-Modifying Proteins) in Class B1 GPCRs Intracellular calcium signaling pathways Development of biosensors for receptor activity screening He employs multidisciplinary approaches combining pharmacological assays, computational modeling, and machine learning. His recent publications demonstrate strong focus on adenosine receptor pharmacology, GPCR signaling bias, and therapeutic applications for metabolic/cardiovascular disorders. Research frequently appears in high-impact journals with significant industry collaboration themes. Honors include: Fellow of the British Pharmacological Society (2020) Royal Society Industry Fellowship for collaboration with AstraZeneca He leads a 17-member research group investigating GPCR signaling dynamics and maintains active industry partnerships with GSK, Takeda, and AstraZeneca. His teaching includes lectures on drug-receptor interactions and diabetes therapeutics for medical/natural sciences students. Laboratory activities focus on: BRET-based molecular probing of GPCR interactions Development of computational models for receptor activation Calcium signaling studies continuing legacy of Professor Colin Taylor Industry-linked drug discovery projects

Jens Carlssonمشاهده پروفایل

استاد

• G protein-coupled receptors (GPCRs)
• Structure-based drug design
• Molecular docking
• +۷ مورد دیگر

Jens Carlsson is a Professor at Uppsala University, affiliated with the Department of Cell and Molecular Biology and the Science for Life Laboratory (SciLifeLab) . His research focuses on computational biochemistry , particularly G protein-coupled receptors (GPCRs) , using physics-based modeling to advance structure-based drug design . Academic rank: Full Professor (since 2022) Key methodologies: Molecular dynamics simulations, docking, free energy calculations Research themes: GPCR ligand interactions, virtual chemical space screening, allosteric modulators Recent work (2025) highlights AI-driven discovery of brain disease therapeutics and DNA repair inhibitors , while 2024 projects explore AlphaFold applications in TAAR1 agonist design . His group has received Swedish Research Council grants (3.6M SEK, 6M SEK) and industry collaborations . Scientific awards include the Göran Gustafsson Prize (2016), Excellence Prize in Molecular Design (2022), and Ingvar Carlsson Award (2012). Key students include PhD candidates Mariama Jaiteh and Pierre Matricon , with postdocs like Nicolas Panel and Duy Duc Vo .

• Medicinal Chemistry
• Molecular Pharmacology
• Neuroscience
• +۵ مورد دیگر

Professor Mary Collins is a Professor of Pharmaceutical Neuroscience at the University of Sydney , affiliated with the Sydney School of Medical Sciences . She serves as Interim Associate Dean, Research and Head of School . Member of the Centre for Drug Discovery Innovation Member of the Brain and Mind Centre Research Interests GABA Receptors : Focus on subtype-selective modulators, binding site identification, and roles in anxiety, sleep disorders, and epilepsy. Nicotinic Acetylcholine Receptors : Structure-function studies using site-directed mutagenesis and reactive probes to understand ligand binding. Drug Discovery : SAR studies for selective agents targeting Cys-loop receptors, including flavonoids and cannabinoids. Scientific Contributions Her 15 most recent articles (2020-2024) span epilepsy genetics , receptor stoichiometry , neuroprotective flavonoids , and cannabinoid interactions . Key themes include precision medicine for receptor variants and neurotransmitter modulation in disorders. ASCEPT Young Investigator Award RACI Biota Award Fellow of RACI (2006) Supervision Award (University of Sydney, 2008) Advising Current students: Jacinda HOLTSMARK (epilepsy neurophysiology), Sze Hon KAN (genetic epilepsies), Fiona WANG (neurological mechanisms).

• Neuroimaging
• PET Imaging
• Radiopharmaceutical Development
• +۵ مورد دیگر

Maeva Dhaynaut is an Instructor in the Department of Radiology & Biomedical Imaging at Yale School of Medicine. Her academic appointment is within the Division of Bioimaging Sciences, focusing on positron emission tomography (PET) research and applications. Dr. Dhaynaut's research spans multiple areas of molecular and neuroimaging, with particular emphasis on: Development and application of PET radiotracers for neurological disorders Tau imaging in Alzheimer's disease and related neurodegenerative conditions Opioid receptor imaging and neuropsychiatric applications Quantitative imaging methods and kinetic modeling Novel radiopharmaceutical development for CNS targets Her recent publications demonstrate strong expertise in tau PET imaging with tracers like [18F]MK6240, with applications ranging from Alzheimer's disease to sports-related neurodegeneration in former football players. She has also made significant contributions to opioid receptor imaging and potassium channel imaging. Dr. Dhaynaut frequently employs advanced computational methods including diffusion models and Bayesian approaches for kinetic parameter estimation in dynamic PET imaging. Dr. Dhaynaut's collaborative research network includes prominent scientists such as Georges El Fakhri, Marc David Normandin, and Nicolas Guehl. Her work spans from basic radiopharmaceutical chemistry through preclinical validation to clinical applications, demonstrating a comprehensive translational research approach.

Gerhard Wolberمشاهده پروفایل

استاد

• Computational Drug Design
• G-Protein Coupled Receptors (GPCRs)
• Cytochrome P450 Enzymes
• +۳ مورد دیگر

Professor Gerhard Wolber leads the Molecular Drug Design research group at the Institute of Pharmacy , Freie Universitaet Berlin. His work focuses on computational approaches to drug discovery, with expertise in G-protein coupled receptors (GPCRs) , cytochrome P450 enzymes , Toll-like receptors , and viral protease inhibitors . He supervises a team of 13 PhD candidates 3 researchers 2 Master's students engaged in projects ranging from calcium channel blockers to CYP enzyme modulators for cancer therapy. Recent publications highlight his lab's contributions to pan-coronavirus drug discovery, TLR8 antagonism, and calcium channel inhibition. The team employs advanced methodologies including Molecular dynamics simulations Fragment-based de novo design Bayesian neural networks DFT calculations 3D pharmacophore modeling to bridge computational predictions with experimental validation. Notable projects include Virtual screening for TREM2-targeted glioblastoma therapeutics Allosteric communication path analysis via MDPath Immune checkpoint inhibitors for cancer immunotherapy Biased GPCR ligand development demonstrating a multidisciplinary approach to contemporary drug design challenges.

• Computational Drug Design
• Molecular Modeling
• Anticancer Agents
• +۵ مورد دیگر

Dr. Vibhu Jha is an Assistant Professor at the Institute of Cancer Therapeutics , part of the School of Pharmacy & Medical Sciences at the University of Bradford . He holds a PhD from the University of Pisa (Italy) with a focus on computational drug discovery, followed by postdoctoral research at the University of Gothenburg (Sweden) and the University of Dundee (UK). His expertise lies in computational modeling techniques (e.g., molecular docking, machine learning) for anticancer drug design, targeting pathways like 1C metabolism and EGFR-driven resistance. Education: B.Pharm, Chhattisgarh Swami Vivekananda Technical University (2008–2012) M.S. Pharm (Medicinal Chemistry), National Institute of Pharmaceutical Education and Research (2013–2015) PhD, University of Pisa (2017–2021) Research Focus: Dr. Jha’s work integrates AI/ML with conventional computational methods to study protein interactions (e.g., protein-ligand, protein-DNA) and develop inhibitors against cancer targets. Key projects include: Targeting MTHFD2/SHMT2 in breast/colorectal cancers Designing dual EGFR/ACK1 inhibitors for lung cancer Developing topoisomerase-HDAC dual inhibitors His research also explores drug repurposing and collaborative projects with institutions in Italy, Sweden, Germany, and India. Awards: 8 awards (specific names not listed in available texts). Advising & Collaboration: Supervised master’s projects at the University of Gothenburg. Collaborates with Prof. Raj Kumar (Central University of Punjab), Prof. Leif Eriksson (University of Gothenburg), and Prof. Tiziano Tuccinardi (University of Pisa). Active in computational drug design, AI-driven predictive models, and structure-based drug design. Labs & Teams: Based at the Institute of Cancer Therapeutics, Bradford. Engaged in cross-disciplinary teams focused on computational oncology and translational drug discovery.

Christoph Diehlمشاهده پروفایل

پژوهشگر

• Synthetic Biology
• Biocatalysis
• Metabolic Engineering
• +۶ مورد دیگر

Dr. Christoph Diehl is a researcher at the Faculty of Chemistry , affiliated with the Organic Chemistry and Biocatalysis Group at the University of Bielefeld . His work focuses on synthetic biology and biocatalysis, particularly in developing biochemical systems for CO 2 fixation and complex molecule synthesis. Current Affiliation: University of Bielefeld, Faculty of Chemistry Research Group: Organic Chemistry and Biocatalysis / Center for Biotechnology (CeBiTec) Research Interests Dr. Diehl specializes in: Designing synthetic CO 2 fixation cycles (THETA, HOPAC) Developing in vitro biochemical networks Engineering biocatalytic enzyme cascades Optimizing carbon utilization for chemical production Integrating machine learning with metabolic engineering Creating cell-free systems for biomanufacturing Publication Trends His recent work emphasizes synthetic CO 2 fixation pathways, biocatalytic cascade design, and machine learning-guided optimization of metabolic systems. He has pioneered modular approaches for terpene/polyketide synthesis from CO 2 and developed novel carboxylation modules.